GlassScriptPhysician profile
Angela D Hunt
NPI 1992800924
$2,983.58
in general payments reported to CMS, 2019-2025
28 companies · $714 in 2025
The $714 reported for 2025 was more than what 96% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $495 · 2020: $62.76 · 2021: $652 · 2022: $376 · 2023: $178 · 2024: $505 · 2025: $714.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,397.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,396.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $340.85 | 2019-2024 | Auvi-Q |
| Corium, LLC | $323.17 | 2022-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $318.72 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $222.73 | 2019-2025 | Gardasil 9, M-M-R II, Vaxelis |
| Glaxosmithkline, LLC. | $215.35 | 2019-2025 | Bexsero |
| Collegium Pharmaceutical, INC. | $213.60 | 2025 | Jornay Pm |
| Teva Pharmaceuticals USA, INC. | $203.90 | 2021 | |
| Pfizer INC. | $198.49 | 2019-2024 | |
| Supernus Pharmaceuticals, INC. | $168.91 | 2025 | Qelbree |
| Cranial Technologies, INC | $100.01 | 2024-2025 | Doc Band |
| Alexion Pharmaceuticals, INC. | $79.39 | 2021-2024 | Strensiq |
| Alk-Abello, INC | $62.62 | 2025 | Neffy |
| Tris Pharma INC | $58.23 | 2019-2020 | |
| Shire North American Group INC | $42.88 | 2019 | |
| Lnhc, INC | $41.46 | 2025 | Zelsuvmi |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $41.35 | 2019 | |
| Sanofi Pasteur INC. | $41.28 | 2023-2024 | |
| Phadia US INC. | $38.68 | 2019-2025 | Immunocap |
| Seqirus USA INC | $38.56 | 2024 | Flucelvax |
| Kowa Pharmaceuticals America, INC. | $38.02 | 2024-2025 | Zoryve |
| Genentech USA, INC. | $36.36 | 2021 | |
| Mylan Pharmaceuticals INC. | $31.42 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.43 | 2022 | |
| Soleno Therapeutics, INC. | $23.92 | 2025 | Vykat Xr |
| Dermira, INC. | $23.48 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $22.32 | 2019 | |
| Hologic Sales and Service, LLC | $21.45 | 2023 | Aptima, Affirm Prone Biopsy System |
| Organon LLC | $9.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Hunt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.